CL2018000927A1 - Terapia combinada para el tratamiento de neoplasias malignas - Google Patents

Terapia combinada para el tratamiento de neoplasias malignas

Info

Publication number
CL2018000927A1
CL2018000927A1 CL2018000927A CL2018000927A CL2018000927A1 CL 2018000927 A1 CL2018000927 A1 CL 2018000927A1 CL 2018000927 A CL2018000927 A CL 2018000927A CL 2018000927 A CL2018000927 A CL 2018000927A CL 2018000927 A1 CL2018000927 A1 CL 2018000927A1
Authority
CL
Chile
Prior art keywords
treatment
combined therapy
malignant neoplasms
treat aml
idh2
Prior art date
Application number
CL2018000927A
Other languages
English (en)
Spanish (es)
Inventor
Samuel V Agresta
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CL2018000927A1 publication Critical patent/CL2018000927A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2018000927A 2015-10-15 2018-04-11 Terapia combinada para el tratamiento de neoplasias malignas CL2018000927A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562242256P 2015-10-15 2015-10-15
US201562255194P 2015-11-13 2015-11-13

Publications (1)

Publication Number Publication Date
CL2018000927A1 true CL2018000927A1 (es) 2018-09-14

Family

ID=57208385

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000927A CL2018000927A1 (es) 2015-10-15 2018-04-11 Terapia combinada para el tratamiento de neoplasias malignas

Country Status (15)

Country Link
US (2) US10905692B2 (enExample)
EP (2) EP4147692A1 (enExample)
JP (2) JP2018534288A (enExample)
KR (2) KR20180063125A (enExample)
CN (1) CN108366980A (enExample)
AU (1) AU2016340087C1 (enExample)
BR (1) BR112018007304A2 (enExample)
CA (1) CA3001599A1 (enExample)
CL (1) CL2018000927A1 (enExample)
EA (1) EA201890968A1 (enExample)
IL (2) IL311873A (enExample)
MX (2) MX394796B (enExample)
SG (1) SG10201912886XA (enExample)
WO (1) WO2017066599A1 (enExample)
ZA (1) ZA201802088B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017529382A (ja) 2014-09-29 2017-10-05 アギオス ファーマシューティカルス，インコーポレーテッド 治療活性を有する化合物及びその使用方法
JP7220986B6 (ja) 2015-02-04 2024-02-08 アジオス ファーマシューティカルズ， インコーポレイテッド 治療効果のある化合物及びその使用方法
US10695352B2 (en) 2015-10-15 2020-06-30 Celgene Corporation Combination therapy for treating malignancies
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
MX392941B (es) 2016-09-07 2025-03-24 Celgene Corp Composiciones para comprimidos.
WO2018204787A1 (en) 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
CA3069558A1 (en) * 2017-07-09 2019-01-17 Biosight Ltd. Combination cancer therapy
US10980788B2 (en) * 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
US20220017490A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
US20220017489A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Solid dispersions for treatment of cancer
JP2023503842A (ja) 2019-11-14 2023-02-01 セルジーン コーポレーション がんを処置するための小児用製剤
CN111087408B (zh) * 2020-01-03 2021-04-02 浙江大学 一种大环结构的idh2突变体抑制剂及其医药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
DE60123384T2 (de) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
EP2525790B1 (en) * 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
PE20142098A1 (es) 2012-01-06 2015-01-08 Agios Pharmaceuticals Inc Compuestos terapeuticamente activos y sus metodos de uso
AU2014287122B9 (en) 2013-07-11 2018-11-01 Les Laboratoires Servier N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
AU2014295938B2 (en) * 2013-08-02 2018-07-19 Les Laboratoires Servier Therapeutically active compounds and their methods of use
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
JP2017529382A (ja) 2014-09-29 2017-10-05 アギオス ファーマシューティカルス，インコーポレーテッド 治療活性を有する化合物及びその使用方法
JP7220986B6 (ja) 2015-02-04 2024-02-08 アジオス ファーマシューティカルズ， インコーポレイテッド 治療効果のある化合物及びその使用方法
US9751863B2 (en) 2015-08-05 2017-09-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10695352B2 (en) 2015-10-15 2020-06-30 Celgene Corporation Combination therapy for treating malignancies
ES2905915T3 (es) 2015-12-04 2022-04-12 Servier Lab Procedimientos de tratamiento de neoplasias malignas
MA43640A (fr) 2016-02-26 2018-11-28 Agios Pharmaceuticals Inc Inhibiteurs de idh1 pour le traitement de cancers hématologiques et de tumeurs solides

Also Published As

Publication number Publication date
MX2022006701A (es) 2022-07-12
JP2021130682A (ja) 2021-09-09
KR20250065944A (ko) 2025-05-13
AU2016340087C1 (en) 2022-08-18
CN108366980A (zh) 2018-08-03
IL258269A (en) 2018-05-31
MX394796B (es) 2025-03-24
ZA201802088B (en) 2021-07-28
US20210386749A1 (en) 2021-12-16
KR20180063125A (ko) 2018-06-11
NZ740792A (en) 2024-05-31
US20180311249A1 (en) 2018-11-01
AU2016340087B2 (en) 2022-05-12
MX2018004595A (es) 2019-07-04
WO2017066599A1 (en) 2017-04-20
BR112018007304A2 (pt) 2018-10-23
US10905692B2 (en) 2021-02-02
AU2016340087A1 (en) 2018-04-12
EP3362057A1 (en) 2018-08-22
JP2018534288A (ja) 2018-11-22
SG10201912886XA (en) 2020-02-27
IL311873A (en) 2024-06-01
CA3001599A1 (en) 2017-04-20
EP4147692A1 (en) 2023-03-15
EA201890968A1 (ru) 2018-09-28

Similar Documents

Publication Publication Date Title
CL2018000927A1 (es) Terapia combinada para el tratamiento de neoplasias malignas
CL2018000955A1 (es) Terapia de combinación para el tratamiento de neoplasias malignas
MX2018004587A (es) Terapia de combinacion para tratar tumores malignos.
CL2018000943A1 (es) Terapia de combinación para tratar tumores malignos
ZA202208792B (en) Methods of treating and preventing graft versus host disease
CL2015002807A1 (es) Terapia de combinación
EA201790737A1 (ru) Комбинированная терапия
MX391229B (es) Metodos de tratamiento de neoplasias malignas.
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
EP4552698A3 (en) Methods of treating prostate cancer
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
MY201580A (en) Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
MX2020001727A (es) Terapia de combinacion.
MX2016015161A (es) Metodos de tratamiento de cancer de mama luminal a positivo para pr con inhibidor de pi3k, pictilisib.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
CR20140480A (es) Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek
EA201890956A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
EA201990411A1 (ru) Способы лечения рака предстательной железы
EA201691907A1 (ru) Комбинированная терапия кураксинами
NI201300052A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek